|

BTX-A51 Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: (1r,4r)-N 1-(5-chloro-4-(5-(cyclopropylmethyl)-1-methyl-l H pyrazol-3-yl)pyrimidin-2-yl)cyclohexane-l ,4-diamine bis(4-methylbenzenesulfonate),, C32H41ClN6O6S2

Pipeline

Phase 1: 2

Top Sponsors

  • Edgewood Oncology Inc.2

Indications

  • Cancer2
  • Metastatic Breast Cancer1
  • Myelodysplastic Syndrome1
  • Acute Myeloid Leukemia1
  • Advanced Solid Tumor1

Duarte, California1 trial

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

City of Hope National Medical Center

Phase 1

Lake Mary, Florida1 trial

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Florida Cancer Specialists

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.